menu
    • menu
    [{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Vonoprazan Fumarate","moa":"||K-ATPase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Phathom Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Phathom Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Phathom Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Vonoprazan Fumarate","moa":"||K-ATPase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Phathom Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Phathom Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Phathom Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Vonoprazan Fumarate","moa":"||K-ATPase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Phathom Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Phathom Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Phathom Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Phathom Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Vonoprazan Fumarate","moa":"||K-ATPase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Catalent Pharma Solutions \/ Phathom Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Catalent Pharma Solutions \/ Phathom Pharmaceuticals"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Phathom Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Vonoprazan Fumarate","moa":"||K-ATPase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Catalent Pharma Solutions \/ Phathom Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Catalent Pharma Solutions \/ Phathom Pharmaceuticals"},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vonoprazan Fumarate","moa":"||K-ATPase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Phathom Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Phathom Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Phathom Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Vonoprazan Fumarate","moa":"||K-ATPase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Phathom Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Phathom Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Phathom Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Vonoprazan Fumarate","moa":"||K-ATPase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Phathom Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Phathom Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Phathom Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Vonoprazan Fumarate","moa":"||K-ATPase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Phathom Pharmaceuticals","amount2":0.26000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Phathom Pharmaceuticals \/ Morgan Stanley","highestDevelopmentStatusID":"15","companyTruncated":"Phathom Pharmaceuticals \/ Morgan Stanley"},{"orgOrder":0,"company":"Evonik","sponsor":"Phathom Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Vonoprazan Fumarate","moa":"||K-ATPase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Evonik","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Evonik \/ Phathom Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Evonik \/ Phathom Pharmaceuticals"}]

    Find Infections and Infectious Diseases Clinical Drug Pipeline Developments & Deals for Vonoprazan Fumarate

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Evonik

                            Germany
                            CPhI WW Frankfurt
                            Booth #6.1B44
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothEvonik's CDMO solutions for APIs and HPAPIs: It specializes where the client needs it most!

                            Lead Product(s) : Vonoprazan Fumarate,Amoxicillin Trihydrate,Clarithromycin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Sponsor : Phathom Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Evonik and Phathom Pharmaceuticals Partner to Produce Novel Acid-Blocker Vonoprazan

                            Details : Vonoprazan is a novel potassium-competitive acid blocker (PCAB). It inhibits gastric acid secretion by acting as a reversible competitive inhibitor against potassium ions.

                            Product Name : Voquezna Triple Pack

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            October 24, 2022

                            Lead Product(s) : Vonoprazan Fumarate,Amoxicillin Trihydrate,Clarithromycin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Phathom Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            Evonik company banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Phathom Pharmaceuticals

                            U.S.A arrow
                            Vietnam Medi-Pharm Expo
                            Not Confirmed

                            Phathom Pharmaceuticals

                            U.S.A arrow
                            Vietnam Medi-Pharm Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vonoprazan Fumarate,Amoxicillin Trihydrate,Clarithromycin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phathom Pharmaceuticals Announces FDA Approval of Reformulated Vonoprazan Tablets for VOQUEZNA® TRIPLE PAK® ...

                            Details : VOQUEZNA® TRIPLE PAK® (vonoprazan, amoxicillin, clarithromycin) contain vonoprazan, an oral small molecule potassium-competitive acid blocker (PCAB) co-packaged with antibiotics. It has been approved by FDA for the treatment of H. pylori infection in a...

                            Product Name : Voquezna Triple Pak

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            October 30, 2023

                            Lead Product(s) : Vonoprazan Fumarate,Amoxicillin Trihydrate,Clarithromycin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Catalent Pharma Solutions

                            U.S.A arrow
                            Vietnam Medi-Pharm Expo
                            Not Confirmed

                            Catalent Pharma Solutions

                            U.S.A arrow
                            Vietnam Medi-Pharm Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vonoprazan Fumarate,Amoxicillin Trihydrate,Clarithromycin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Sponsor : Phathom Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Catalent Supports U.S. Launch of Phathom Pharmaceuticals’ New Products Following Regulatory Approval

                            Details : Voquezna (vonoprazan) new treatment options contain antibiotics conveniently packaged with vonoprazan, a novel potassium-competitive acid blocker (PCAB) and the first innovative acid suppressant from a new drug class approved in the U.S. in over 30 years...

                            Product Name : Voquezna

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            September 06, 2022

                            Lead Product(s) : Vonoprazan Fumarate,Amoxicillin Trihydrate,Clarithromycin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Phathom Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Phathom Pharmaceuticals

                            U.S.A arrow
                            Vietnam Medi-Pharm Expo
                            Not Confirmed

                            Phathom Pharmaceuticals

                            U.S.A arrow
                            Vietnam Medi-Pharm Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vonoprazan Fumarate,Amoxicillin Trihydrate,Clarithromycin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phathom Pharmaceuticals Presents Data on Novel Potassium-Competitive Acid Blocker (PCAB) Vonoprazan from a Ran...

                            Details : VOQUEZNA TRIPLE PAK (vonoprazan, amoxicillin, clarithromycin) is an orally administered potassium-competitive acid blocker from a new class of acid suppressant agents and under development for treatment of erosive esophagitis and non-erosive gastroesopha...

                            Product Name : Vaquezna Triple Pak

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 24, 2022

                            Lead Product(s) : Vonoprazan Fumarate,Amoxicillin Trihydrate,Clarithromycin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Phathom Pharmaceuticals

                            U.S.A arrow
                            Vietnam Medi-Pharm Expo
                            Not Confirmed

                            Phathom Pharmaceuticals

                            U.S.A arrow
                            Vietnam Medi-Pharm Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vonoprazan Fumarate,Amoxicillin Trihydrate,Clarithromycin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Sponsor : Morgan Stanley

                            Deal Size : $260.0 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Phathom Pharmaceuticals Announces Revenue Interest Financing Agreement for Up to $260 Million in Non-Dilutive ...

                            Details : The signing of this agreement both validates the belief in the blockbuster opportunity of Voquenza (vonoprazan) and provides near-term, non-dilutive funding for continued development activities and upcoming commercial launch.

                            Product Name : Vaquezna Triple Pak

                            Product Type : Other Small Molecule

                            Upfront Cash : $100.0 million

                            April 05, 2022

                            Lead Product(s) : Vonoprazan Fumarate,Amoxicillin Trihydrate,Clarithromycin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Morgan Stanley

                            Deal Size : $260.0 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Phathom Pharmaceuticals

                            U.S.A arrow
                            Vietnam Medi-Pharm Expo
                            Not Confirmed

                            Phathom Pharmaceuticals

                            U.S.A arrow
                            Vietnam Medi-Pharm Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vonoprazan Fumarate,Amoxicillin Trihydrate

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA™ TRIPLE PAK™ (Vonoprazan, Amoxicillin, Clarithr...

                            Details : VOQUEZNA TRIPLE and DUAL PAKs each contain vonoprazan, a novel, first-in-class potassium-competitive acid blocker (PCAB), and have demonstrated superior eradication rates vs. lansoprazole-based triple therapy in the overall patient population of the pivo...

                            Product Name : Voquezna Dual Pak

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 05, 2022

                            Lead Product(s) : Vonoprazan Fumarate,Amoxicillin Trihydrate

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Phathom Pharmaceuticals

                            U.S.A arrow
                            Vietnam Medi-Pharm Expo
                            Not Confirmed

                            Phathom Pharmaceuticals

                            U.S.A arrow
                            Vietnam Medi-Pharm Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vonoprazan Fumarate,Amoxicillin Trihydrate,Clarithromycin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA TRIPLE PAK (vonoprazan, amoxicillin, clarithromycin...

                            Details : Vaquezna (vonoprazan)TRIPLE and DUAL PAKs each contain vonoprazan, a novel, first-in-class potassium-competitive acid blocker, and have demonstrated superior eradication rates vs. lansoprazole-based triple therapy in overall patient population of pivotal...

                            Product Name : Vaquezna Triple Pak

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 05, 2022

                            Lead Product(s) : Vonoprazan Fumarate,Amoxicillin Trihydrate,Clarithromycin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Phathom Pharmaceuticals

                            U.S.A arrow
                            Vietnam Medi-Pharm Expo
                            Not Confirmed

                            Phathom Pharmaceuticals

                            U.S.A arrow
                            Vietnam Medi-Pharm Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vonoprazan Fumarate,Amoxicillin Trihydrate

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phathom Pharmaceuticals to Present New Data at ACG 2021 Annual Scientific Meeting

                            Details : Vonoprazan has shown the potential to have rapid, potent, and durable anti-secretory effects as a single agent in the treatment of gastroesophageal reflux disease (GERD) and in combination with antibiotics for the treatment of Helicobacter pylori (H. pyl...

                            Product Name : Voquezna Dual Pak

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            October 21, 2021

                            Lead Product(s) : Vonoprazan Fumarate,Amoxicillin Trihydrate

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Catalent Pharma Solutions

                            U.S.A arrow
                            Vietnam Medi-Pharm Expo
                            Not Confirmed

                            Catalent Pharma Solutions

                            U.S.A arrow
                            Vietnam Medi-Pharm Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vonoprazan Fumarate,Amoxicillin Trihydrate

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Phathom Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Catalent Signs Commercial Supply Agreement with Phathom Pharmaceuticals

                            Details : Under the terms of the agreement, should the drug receive FDA approval for its lead product vonoprazan. Catalent will undertake the commercial manufacturing and packaging of the product at its large-scale oral solid dose manufacturing site in Winchester,...

                            Product Name : Voquezna Dual Pak

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            September 16, 2021

                            Lead Product(s) : Vonoprazan Fumarate,Amoxicillin Trihydrate

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Phathom Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Phathom Pharmaceuticals

                            U.S.A arrow
                            Vietnam Medi-Pharm Expo
                            Not Confirmed

                            Phathom Pharmaceuticals

                            U.S.A arrow
                            Vietnam Medi-Pharm Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vonoprazan Fumarate,Amoxicillin Trihydrate

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phathom Pharmaceuticals Submits Two NDAs to U.S. FDA for Vonoprazan-based Treatment Regimens for the Treatment...

                            Details : Phathom Pharmaceuticals has submitted two NDAs to the U.S. FDA for the use of vonoprazan in combination with amoxicillin and clarithromycin and vonoprazan in combination with amoxicillin as a treatment for Helicobacter pylori (H. pylori) infection in adu...

                            Product Name : Voquezna Dual Pak

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            August 09, 2021

                            Lead Product(s) : Vonoprazan Fumarate,Amoxicillin Trihydrate

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth